A simple nasal spray, instead of an injection, which is now charged to the National Health Service, and therefore reimbursable for the citizen. It is Baqsimi, a medicine based on glucagon nasal powder: the decision, outcome of the evaluation of the Aifa Price and Reimbursement Commission (the Italian Medicines Agency) was made official with the publication in the Official Gazette. With the decision of Aifa, the Region will therefore take steps to make the administration of the drug available by means of the spray, even if the traditional administration by injection will continue to remain available.
“As promised, now the Emilia-Romagna Region will guarantee the availability of Baqsimi through the Regional Medicines Commission – underlines the regional councilor for health policies, Raffaele Donini -: we know how much the Aifa pronouncement was expected, especially by of parents with children suffering from diabetes mellitus. At the same time – adds the commissioner – the Region will promote adequate training on the use of the medicine among those who will have to administer it, and therefore health professionals, operators, caregivers. All this to ensure appropriateness, effectiveness and safety of therapeutic intervention in urgency “.
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents and children 4 years of age and older with diabetes mellitus. Compared to the injection, it is a simple spray, and therefore easier to administer – for example, at school – in case of need. Furthermore, it does not need a refrigerator to be stored. Available in Italy from the summer of 2020, until now it was possible to buy it at the price of 140.29 euros, with a medical prescription (repeatable white prescription), according to a classification that until now did not provide for the reimbursement of the drug.